Insulin-like growth factor system and the kidney: Physiology, pathophysiology, and therapeutic implications
Abstract
The insulin-like growth factor (IGF) system, consisting of IGF-I and IGF-II, their binding proteins, and their receptors, is expressed in a spatial organization in the nephron, but circulating IGFs also affect the kidney. Renal and systemic IGF-I and the binding proteins are regulated by growth hormone and nutritional status. In the kidney, IGF- I dilates the resistance-regulating microvasculature, increases glomerular filtration rate, and promotes tubular phosphate and possibly sodium absorption. IGF-I contributes to compensatory renal growth in a variety of experimental models and may modestly contribute to progressive glomerular sclerosis. In chronic renal failure and the nephrotic syndrome, there are several abnormalities in the IGF system. In chronic renal failure, IGF-I increases renal function and may improve nutritional status due to its anabolic effects. IGF-I accelerates the recovery of renal function in animal models of acute renal failure, but results from clinical trials were less salutary. Several questions regarding the role of the IGF system in normal and abnormal renal biology and potential therapeutic applications in kidney diseases remain unanswered. (Am J Kidney Dis 1998 Jun;31(6):901-19)
References (0)
Cited by (90)
Anabolic and anticatabolic agents in kidney disease and kidney failure
2021, Nutritional Management of Renal Disease, Fourth EditionPoor physical function and muscle weakness are associated with higher mortality in chronic kidney disease and end-stage renal disease patients. Studies have tested therapeutic agents to prevent and mitigate muscle wasting with the hope of maintaining or even increasing physical function. Anabolic pathways in muscle largely signal through the insulin-like growth factor-1/PI3K/Akt system. Several therapeutic agents have been found to stimulate this pathway, such as testosterone, growth hormone (GH), and vitamin D. The ubiquitin–proteasome system is the major catabolic pathway in skeletal muscle. This pathway is stimulated by myostatin, which decreases anabolic signaling and induces catabolic signaling. Several therapeutic agents have been developed to counter myostatin action. In this chapter, we review the history, molecular mechanisms, in vitro and in vivo data, and clinical trial data for each of these therapeutic agents: testosterone, GH, vitamin D, and antimyostatin antibodies.
Decreased number of CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> regulatory B cells in Diabetic nephropathy
2019, Molecular ImmunologyRegulatory B cells participate in the pathogenesis of autoimmune disease. This study aimed to examine the putative contribution of regulatory B cells to the pathogenesis of DN. The number of circulating CD19+CD24hiCD38hi B cells, CD19+CD24hiCD38hiCD5+ B cells, and CD19+CD24hiCD38hiIL-10+ B cells were significantly lower in DN patients (p < 0.05) than the control group. The number of circulating CD19+CD24hiCD38hi B cells was positively correlated with the levels of eGFR and serum IL-10 levels, but negatively correlated with urinary protein levels in DN patients. Treatment significantly increased the number of CD19+CD24hiCD38hi B cells, CD19+CD24hiCD38hiCD5+ B cells, CD19+CD24hiCD38hiIL-10+ B cells, and the levels of serum IL-10 (p < 0.05). We conclude that regulatory B cells may present new targets for intervention of DN.
Growth Hormone
2017, Textbook of Nephro-EndocrinologyGrowth hormone (GH) is a key mediator of growth and anabolic activities and primarily exerts its effects by stimulating production of insulin-like growth factor-1 (IGF-1). The production and interactions of GH and IGF-1 are complex and are significantly transformed in individuals with acute and chronic renal insufficiency, related to level of renal impairment, nutritional status, altered systemic hormones, and sex steroids (estrogen, testosterone). The GH/IGF-1 axis is most importantly a regulator of growth and metabolism, but abnormalities in this axis may lead to a variety of other systemic effects including decreased muscle mass, decreased bone mass, impaired neurocognitive development, disordered plasma lipids, and significant morbidity and increased mortality. Proper recognition and appropriate management of GH/IGF-1 abnormalities can lead to decreased morbidity in children and adults with chronic kidney disease (CKD). This represents an important framework in the care of individuals with CKD and there is preliminary evidence that there is improvement in care of children and adults with acute renal failure.
Recombinant human GH is now well established as a useful therapy for growth failure in children with CKD. The potential for GH therapy to improve nutrition in adult patients on hemodialysis appears very promising. Recombinant GH therapy in both children and adults with CKD may have muscle strength, psychosocial, and other benefits. Future studies will establish if there is any role for recombinant human IGF-1 therapy in the management of children and adults with CKD.
Therapeutic Use of Growth Factors in Renal Disease
2013, Nutritional Management of Renal DiseaseThe insulin-like growth factor system in chronic kidney disease: Pathophysiology and therapeutic opportunities
2012, Kidney Research and Clinical PracticeCitation Excerpt :This involves activation of IGF-independent IGFBP-3 signaling and cross-talk with nuclear factor-kappa B signaling. The IGF system is expressed in a complicated manner within the kidney and has profound effects on kidney growth, structure, and function [50–53]. However, less information is available about the expression of the IGF system in human kidney.
The growth hormone–insulin-like growth factor–insulin-like growth factor binding protein (GH–IGF–IGFBP) axis plays a critical role in the maintenance of normal renal function and the pathogenesis and progression of chronic kidney disease (CKD). Serum IGF-I and IGFBPs are altered with different stages of CKD, the speed of onset, the amount of proteinuria, and the potential of remission. Recent studies demonstrate that growth failure in children with CKD is due to a relative GH insensitivity and functional IGF deficiency. The functional IGF deficiency in CKD results from either IGF resistance due to increased circulating levels of IGFBPs or IGF deficiency due to increased urinary excretion of serum IGF–IGFBP complexes. In addition, not only GH and IGFs in circulation, but locally produced IGFs, the high-affinity IGFBPs, and low-affinity insulin-like growth factor binding protein-related proteins (IGFBP-rPs) may also affect the kidney. With respect to diabetic kidney disease, there is growing evidence suggesting that GH, IGF-I, and IGFBPs are involved in the pathogenesis of diabetic nephropathy (DN). Thus, prevention of GH action by blockade either at the receptor level or along its signal transduction pathway offers the potential for effective therapeutic opportunities. Similarly, interrupting IGF-I and IGFBP actions also may offer a way to inhibit the development or progression of DN. Furthermore, it is well accepted that the systemic inflammatory response is a key player for progression of CKD, and how to prevent and treat this response is currently of great interest. Recent studies demonstrate existence of IGF-independent actions of high-affinity and low-affinity-IGFBPs, in particular, antiinflammatory action of IGFBP-3 and profibrotic action of IGFBP-rP2/CTGF. These findings reinforce the concept in support of the clinical significance of the IGF-independent action of IGFBPs in the assessment of pathophysiology of kidney disease and its therapeutic potential for CKD. Further understanding of GH–IGF–IGFBP etiopathophysiology in CKD may lead to the development of therapeutic strategies for this devastating disease. It would hold promise to use of GH, somatostatin analogs, IGFs, IGF agonists, GHR and insulin-like growth factor-I receptor (IGF-IR) antagonists, IGFBP displacer, and IGFBP antagonists as well as a combination treatment as therapeutic agents for CKD.
Cephalometric craniofacial features of growing patients with chronic renal failure
2012, Archives of Oral BiologyChronic renal failure (CRF) in growing children can affect their physical growth status. The objective of this research was to study the craniofacial morphology of children with CRF as evaluated by cephalometric analysis.
Twenty-three growing children with CRF were included in this study. They were divided into three groups according to age ranges. The age ranges were >5–11 (group 1); >11–14 (group 2); >14–16 (group 3). Another twenty-three matching controls (in age and gender) were also included. Lateral cephalometric radiographs were taken as part of these children's orthodontic records. Lateral cephalometric radiographs were corrected for magnification distortion, digitized, and cephalometric analysis was performed. Data were analysed using ANOVA test.
The results showed that CRF patients in all age groups have statistically significantly decreased posterior cranial base lengths. Posterior facial heights showed a significant decrease in CRF patients in groups 1 and 2. Younger CRF patients (group 1) showed statistically significant increased gonial angle and FH-Mandibular plane angle, SN-Mandibular plane angle and decreased posterior to anterior face height ratio, total anterior facial height (N-Me), Mandibular body length (Go-Me), upper anterior facial height (N-ANS), Y axis length, pterygomaxillary-A point length.
Younger children (groups 1 and 2) with CRF showed a decrease in posterior facial growth (posterior facial height and posterior cranial base) when compared to matching normal controls. This decrease is not significant in older group (group 3). This finding suggests that children with CRF might catch up in growth with normal subjects and most of the earlier retarded growth features disappear with age.